Reduced KIR2DL1 recognition of MHC class I molecules presenting phosphorylated peptides

Journal of Immunology

Volumn 176, Issue 11, 2006, Pages 6762-6769

  Betser Cohen, Gili ^a   Katz, Gil ^a   Gonen Gross, Tsufit ^a   Stern, Noam ^a   Arnon, Tal I ^a   Achdout, Hagit ^a   Gazit, Roi ^a   Mandelboim, Ofer ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINYLTYROSYLASPARTYLASPARTYLALANYLVALYLTYROSYLLYSYLLEUCINE; HLA C ANTIGEN; HLA CW4 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; POLYPEPTIDE; PROTEIN KIR2DL1; SERINE; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ARTICLE; CARCINOGENESIS; CONSENSUS SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; VIRUS INFECTION;

EID: 33646870414     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.11.6762     Document Type: Article

References (46)

1. Trinchieri, G. 1989. Biology of natural killer cells. Adv. Immunol. 47: 187-376.
2. Bottino, C., R. Biassoni, R. Millo, L. Moretta, and A. Moretta. 2000. The human natural cytotoxicity receptors (NCR) that induce HLA class I-independent NK cell triggering. Hum. Immunol. 61: 1-6.
3. Colonna, M., G. Borsellino, M. Falco, G. B. Ferrara, and J. L. Strominger. 1993. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. Proc. Natl. Acad. Sci. USA 90: 12000-12004.
4. Cella, M., A. Longo, G. B. Ferrara, J. L. Strominger, and M. Colonna. 1994. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J. Exp. Med. 180: 1235-1242.
5. Wagtmann, N., S. Rajagopalan, C. C. Winter, M. Peruzzi, and E. O. Long. 1995. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity 3: 801-809.
6. Verbrugge, A., T. de Ruiter, H. Clevers, and L. Meyaard. 2003. Differential contribution of the immunoreceptor tyrosine-based inhibitory motifs of human leukocyte-associated Ig-like receptor-1 to inhibitory function and phosphatase recruitment. Int. Immunol. 15: 1349-1358.
7. Stern, N., G. Markel, T. I. Arnon, R. Gruda, H. Wong, S. D. Gray-Owen, and O. Mandelboim. 2005. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J. Immunol. 174: 6692-6701.
8. Markel, G., H. Achdout, G. Katz, K. L. Ling, M. Salio, R. Gruda, R. Gazit, S. Mizrahi, I. Hanna, T. Gonen-Gross, et al. 2004. Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients. Eur. J. Immunol. 34: 2138-2148.
9. Markel, G., N. Lieberman, G. Katz, T. I. Arnon, M. Lotem, O. Drize, R. S. Blumberg, E. Bar-Haim, R. Mader, L. Eisenbach, and O. Mandelboim. 2002. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J. Immunol. 168: 2803-2810.
10. Assarsson, E., T. Kambayashi, C. M. Persson, B. J. Chambers, and H. G. Ljunggren. 2005. 2B4/CD48-mediated regulation of lymphocyte activation and function. J. Immunol. 175: 2045-2049.
11. Eissmann, P., L. Beauchamp, J. Wooters, J. C. Tilton, E. O. Long, and C. Watzl, 2005. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244). Blood 105: 4722-4729,
12. Lanier, L. L. 2005. NK cell recognition, Annu. Rev. Immunol. 23: 225-274.
13. Miller, J. D., D. A. Weber, C. Ibegbu, J. Pohl, J. D. Altman, and P. E. Jensen, 2003. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2. J. Immunol. 171: 1369-1375.
14. Colonna, M., and I. Samaridis. 1995. Cloning of immunoglobulin- superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 268: 405-408.
15. Wagtmann, N., R. Biassoni, C. Cantoni, S. Verdiani, M. S. Malnati, M. Vitale, C. Bottino, L. Moretta, A. Moretta, and E. O. Long. 1995. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. Immunity 2: 439-449.
16. Dohring, C., D. Scheidegger, I. Samaridis, M. Cella, and M. Colonna. 1996. A human killer inhibitory receptor specific for HLA-A 1,2. J. Immunol. 156: 3098-3101.
17. Mandelboim, O., H. T. Reyburn, M. Vales-Gomez, L. Pazmany, M. Colonna, G. Borsellino, and I. L. Strominger. 1996. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J. Exp. Med. 184: 913-922.
18. Winter, C. C., and E. O. Long. 1997. A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J. Immunol. 158: 4026-4028.
19. Rock, K. L., S. Gamble, L. Rothstein, C. Gramm, and B. Benacerraf. 1991. Dissociation of β 2-microglobulin leads to the accumulation of a substantial pool of inactive class I MHC heavy chains on the cell surface. Cell 65: 611-620.
20. Rajagopalan, S., and E. O. Long. 1997. The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity. J. Exp. Med. 185: 1523-1528.
21. Zappacosta, F., F. Borrego, A. G. Brooks, K. C. Parker, and J. E. Coligan. 1997. Peptides isolated from HLA-Cw*0304 confer different degrees of protection from natural killer cell-mediated lysis. Proc. Natl. Acad. Sci. USA 94: 6313-6318.
22. Fan, Q. R., E. O. Long, and D. C. Wiley. 2001. Crystal structure of the human natural killer cell inhibitory receptor KIR2DLl-HLA-Cw4 complex. Nat. Immunol. 2: 452-460.
23. Mandelboim, O., S. B. Wilson, M. Vales-Gomez, H. T. Reyburn, and J. L. Strominger. 1997. Self and viral peptides can initiate lysis by autologous natural killer cells. Proc. Natl. Acad. Sci. USA 94: 4604-4609.
24. Katz, G., G. Markel, S. Mizrahi, T. I. Arnon, and O. Mandelboim. 2001. Recognition of HLA-Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-domain short tail number 4. J. Immunol. 166: 7260-7267.
25. Achdout, H., T. I. Arnon, G. Markel, T. Gonen-Gross, G. Katz, N. Lieberman, R. Gazit, A. Joseph, E. Kedar, and O. Mandelboim. 2003. Enhanced recognition of human NK receptors after influenza virus infection. J. Immunol. 171: 915-923.
26. Zarling, A. L., S. B. Ficarro, F. M. White, J. Shabanowitz, D. F. Hunt, and V. H. Engelhard. 2000. Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. J. Exp. Med. 192: 1755-1762.
27. Falk, K., O. Rotzschke, B. Grahovac, D. Schendel, S. Stevanovic, V. Gnau, G. Jung, I. L. Strominger, and H. G. Rammensee. 1993. Allele-specific peptide ligand motifs of HLA-C molecules. Proc. Natl. Acad. Sci. USA 90: 12005-12009.
28. Sidney, J., M. F. del Guercio, S. Southwood, V. H. Engelhard, E. Appella, H. G. Rammensee, K. Falk, O. Rotzschke, M. Takiguchi, and R. T. Kubo 1995. Several HLA alleles share overlapping peptide specificities. J. Immunol. 154: 247-259.
29. Raulet, D. H. 2003. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 3: 781-790.
30. Routes, J. M., S. Ryan, K. Morris, R. Takaki, A. Cerwenka, and L. L. Lanier. 2005. Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J. Exp. Med. 202: 1477-1482.
31. Germain, R. N., and D. H. Margulies. 1993. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11: 403-450.
32. Lanier, L. L. 1998. NK cell receptors. Annu. Rev. Immunol. 16: 359-393.
33. Andersen, M. H., J. E. Bonfill, A. Neisig, G. Arsequell, I. Sondergaard, G. Valencia, J. Neefjes, J. Zeuthen, T. Elliott, and J. S. Haurum. 1999. Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J. Immunol. 163: 3812-3818.
34. Peruzzi, M., K. C. Parker, E. O. Long, and M. S. Malnati. 1996. Peptide sequence requirements for the recognition of HLA-B*2705 by specific natural killer cells. J. Immunol. 157: 3350-3356.
35. Villanueva, N., J. Navarro, E. Mendez, and I. Garcia-Albert. 1994. Identification of a protein kinase involved in the phosphorylation of the C-terminal region of human respiratory syncytial virus P protein. J. Gen. Virol. 75: 555-565.
36. de Klein, A., A. G. van Kessel, G. Grosveld, C. R. Bartram, A. Hagemeijer, D. Bootsma, N. K. Spurr, N. Heisterkamp, J. Groffen, and J. R. Stephenson. 1982. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300: 765-767.
37. Grasser, F. A., S. Gottel, P. Haiss, B. Boldyreff, O. G. Issinger, and N. Mueller-Lantzsch. 1992. Phosphorylation of the Epstein-Barr virus nuclear antigen 2. Biochem. Biophys. Res. Commun. 186: 1694-1701.
38. Moorthy, R. K., and D. A. Thorley-Lawson. 1993. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J. Virol. 67: 1638-1646.
39. Kolman, J. L., N. Taylor, D. R. Marshak, and G. Miller. 1993. Serine-173 of the Epstein-Barr virus ZEBRA protein is required for DNA binding and is a target for casein kinase II phosphorylation. Proc. Natl. Acad. Sci. USA 90: 10115-10119.
40. Carayannopoulos, L. N., and W. M. Yokoyama. 2004. Recognition of infected cells by natural killer cells. Curr. Opin. Immunol. 16: 26-33.
41. Biassoni, R., C. Cantoni, D. Marras, J. Giron-Michel, M. Falco, L. Moretta, and N. Dimasi. 2003. Human natural killer cell receptors: insights into their molecular function and structure. J. Cell. Mol. Med. 7: 376-387.
42. Bahram, S., H. Inoko, T. Shiina, and M. Radosavljevic. 2005. MIC and other NKG2D ligands: from none to too many. Curr. Opin. Immunol. 17: 505-509.
43. Cerwenka, A., and L. L. Lanier. 2003. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61: 335-343.
44. Arnon, T. I., H. Achdout, O. Levi, G. Markel, N. Saleh, G. Katz, R. Gazit, T. Gonen-Gross, J. Hanna, E. Nahari, et al. 2005. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat. Immunol. 6: 515-523.
45. Mandelboim, O., N. Lieberman, M. Lev, L. Paul, T. I. Arnon, Y. Bushkin, D. M. Davis, J. L. Strominger, J. W. Yewdell, and A. Porgador. 2001. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409: 1055-1060.
46. Arnon, T. I., H. Achdout, N. Lieberman, R. Gazit, T. Gonen-Gross, G. Katz, A. Bar-Ilan, N. Bloushtain, M. Lev, A. Joseph, et al. 2004. The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood 103: 664-672.